Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Nov 18;83(21):1986-7.
doi: 10.1212/WNL.0000000000000997. Epub 2014 Oct 22.

Clinical response to bevacizumab in schwannomatosis

Affiliations
Case Reports

Clinical response to bevacizumab in schwannomatosis

Jaishri Blakeley et al. Neurology. .
No abstract available

PubMed Disclaimer

References

    1. MacCollin M, Chiocca EA, Evans DG, et al. . Diagnostic criteria for schwannomatosis. Neurology 2005;64:1838–1845. - PubMed
    1. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, II, et al. . Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358–367. - PMC - PubMed
    1. Wong HK, Lahdenranta J, Kamoun WS, et al. . Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 2010;70:3483–3493. - PMC - PubMed
    1. Hadfield KD, Newman WG, Bowers NL, et al. . Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 2008;45:332–339. - PubMed
    1. Patil S, Perry A, Maccollin M, et al. . Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 2008;18:517–519. - PMC - PubMed

Publication types

Supplementary concepts